Financings in Brief: Kensey Nash
This article was originally published in The Gray Sheet
Kensey Nash: Plans to go public via initial public offering of 2.7 mil. shares at $11 to $13 per share, the firm announces Oct. 27. The company is currently awaiting final FDA approval for its Angio-Seal hemostasis device after receiving a unanimous approval recommendation from FDA's Circulatory Systems Devices Panel in May ("The Gray Sheet" May 15, p. 8) and an approvable letter from the agency in July. Approximately $10 mil. of the anticipated proceeds from the offering would go toward R&D; $6.6 mil. would go toward debt repayment; $1.9 mil. would repay advances to the company from American Home Products, the firm's marketing and manufacturing partner for Angio-Seal; the remainder would go toward general corporate purposes. Managing underwriters are Janney Montgomery Scott, NatWest Securities Limited and Gerard Klauer Mattison & Co...
You may also be interested in...
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Alpha Source hired a new CEO from Mayline, while Mölnlycke’s CEO comes from CellaVision; Xvivo Perfusion finance chief changed job to become chief operating officer; Shire senior VP now COO at AVITA; and more.